Clinical trial · Observational
The Effect of Albumin Value, HALP Score, and LCR Value on Predicting Survival and Recurrence in Patients With Pancreatic Adenocarcinoma
NCT06553040CI-TRIAL-00079804completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to investigate whether the albumin value and the ratios of biochemical markers; hemoglobin, albumin, lymphocyte and platelet (HALP score) and lymphocyte-C-reactive protein ratio (LCR) can predict the survival and recurrence of the disease in patients with pancreatic adenocarcinoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreas Cancer | Pancreatic Carcinoma | ALIAS | 0.90 |
| Pancreatic Neoplasms | Pancreatic Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- Disease-Free Survival Times
- timeFrame
- 4 Years
- measure
- HALP Score
- timeFrame
- 4 Years
- description
- Hemoglobin x Albumin x Lymphocyte / Platelet
- measure
- Overall Survival Time
- timeFrame
- 4 Years
- measure
- LCR Score
- timeFrame
- 4 Years
- description
- Lymphocyte / CRP
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Whipple operation and total pancreatectomy due to pathologically confirmed pancreatic adenocarcinoma Exclusion Criteria: * Patients with other malignant tumors (choledochal tumor, papilla tumor and duodenal tumor)
References
Publications (0)
Data not yet available
No reference posted for this study.